Menu
Back to User profile » Dr Leslie Citrome
Papers published by Dr Leslie Citrome:
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D
Neuropsychiatric Disease and Treatment 2021, 17:3135-3136
Published Date: 15 October 2021
Tardive Dyskinesia in Older Persons Taking Antipsychotics
Citrome L, Isaacson SH, Larson D, Kremens D
Neuropsychiatric Disease and Treatment 2021, 17:3127-3134
Published Date: 14 October 2021
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D
Neuropsychiatric Disease and Treatment 2021, 17:2885-2904
Published Date: 9 September 2021
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Rosenberg R, Citrome L, Drake CL
Neuropsychiatric Disease and Treatment 2021, 17:2549-2566
Published Date: 6 August 2021
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations
Jackson R, Brams MN, Citrome L, Hoberg AR, Isaacson SH, Kane JM, Kumar R
Neuropsychiatric Disease and Treatment 2021, 17:1589-1597
Published Date: 24 May 2021
Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
Citrome L, Du Y, Weiden PJ
Neuropsychiatric Disease and Treatment 2019, 15:2639-2646
Published Date: 12 September 2019
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ
Neuropsychiatric Disease and Treatment 2019, 15:2559-2569
Published Date: 5 September 2019
Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
Faden J, Citrome L
Neuropsychiatric Disease and Treatment 2019, 15:2273-2283
Published Date: 7 August 2019
Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Ward K, Citrome L
Neuropsychiatric Disease and Treatment 2019, 15:247-257
Published Date: 15 January 2019
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Citrome L
Neuropsychiatric Disease and Treatment 2018, 14:2563-2577
Published Date: 5 October 2018
Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L
ClinicoEconomics and Outcomes Research 2018, 10:443-456
Published Date: 16 August 2018
Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies
Citrome L, Kando JC, Bliss C
Neuropsychiatric Disease and Treatment 2018, 14:537-546
Published Date: 15 February 2018
Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
Citrome L, Landbloom R, Chang C, Earley W
Neuropsychiatric Disease and Treatment 2017, 13:2955-2963
Published Date: 11 December 2017
Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
Durgam S, Chen C, Gommoll CP, Edwards J, Citrome L
Neuropsychiatric Disease and Treatment 2016, 12:3073-3081
Published Date: 2 December 2016
Characteristics of binge eating disorder in relation to diagnostic criteria
Wilfley DE, Citrome L, Herman BK
Neuropsychiatric Disease and Treatment 2016, 12:2213-2223
Published Date: 29 August 2016
Schizophrenia relapse, patient considerations, and potential role of lurasidone
Citrome L
Patient Preference and Adherence 2016, 10:1529-1537
Published Date: 9 August 2016
Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
Citrome L
Therapeutics and Clinical Risk Management 2013, 9:235-245
Published Date: 20 May 2013
Role of sublingual asenapine in treatment of schizophrenia
Citrome L
Neuropsychiatric Disease and Treatment 2011, 7:325-339
Published Date: 26 May 2011
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
Leslie Citrome
Patient Preference and Adherence 2009, 3:345-355
Published Date: 27 November 2009